These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26539647)

  • 1. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
    Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
    Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
    Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA
    Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
    El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
    Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial.
    Lim JH; Jeon Y; Yook JM; Choi SY; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Cho JH
    Sci Rep; 2020 Sep; 10(1):16062. PubMed ID: 32994531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil gelatinase-associated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment.
    Emans ME; Braam B; Diepenbroek A; van der Putten K; Cramer MJ; Wielders JP; Swinkels DW; Doevendans PA; Gaillard CA
    Kidney Blood Press Res; 2012; 36(1):344-54. PubMed ID: 23235391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
    Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
    Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible relationship between neutrophil gelatinase-associated lipocalin, hepcidin, and inflammation in haemodialysed patients.
    Malyszko J; Malyszko JS; Kozminski P; Koc-Zorawska E; Mysliwiec M; Macdougall I
    Nephron Clin Pract; 2010; 115(4):c268-75. PubMed ID: 20424477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
    Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
    Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
    [No Abstract]   [Full Text] [Related]  

  • 11. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
    Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
    PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can serum NGAL levels be used as an inflammation marker on hemodialysis patients with permanent catheter?
    Yigit IP; Celiker H; Dogukan A; Ilhan N; Gurel A; Ulu R; Aygen B
    Ren Fail; 2015 Feb; 37(1):77-82. PubMed ID: 25347233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
    Rubab Z; Amin H; Abbas K; Hussain S; Ullah MI; Mohsin S
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):19-25. PubMed ID: 25579711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
    van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
    PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.
    Kuragano T; Kitamura K; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura Y; Nakanishi T
    PLoS One; 2016; 11(3):e0147328. PubMed ID: 26933949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients.
    Yamamoto M; Matsumoto T; Ohmori H; Takemoto M; Ikeda M; Sumimoto R; Kobayashi T; Kato A; Ohdan H
    BMC Nephrol; 2021 Jun; 22(1):221. PubMed ID: 34126941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
    Okazaki M; Komatsu M; Kawaguchi H; Tsuchiya K; Nitta K
    Blood Purif; 2014; 37(2):106-12. PubMed ID: 24603656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study.
    Fujikawa T; Ikeda Y; Fukuhara S; Akiba T; Akizawa T; Kurokawa K; Saito A
    Nephron Clin Pract; 2012; 122(1-2):24-32. PubMed ID: 23486237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.